Q-omics provides the consensus-scored SART3 profile across patient tissues and cancer cell-line models. SART3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, SART3 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, SART3 protein abundance shows 36,830 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, BLCA, and GBM as cancer lineages where SART3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SART3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SART3 survival associations across molecular data types. SART3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SART3 RNA expression–survival associations across cancer types. High SART3 expression shows unfavorable associations in LIHC, ACC and MESO, but favorable associations in SCLC, UCS and KIRC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for SART3 RNA expression.
This table summarizes SART3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 11. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SART3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SART3 shows higher tumor expression in BLCA, HNSC, COAD, KIRC, KIRP and STAD. The BLCA box plot shows higher SART3 RNA expression in tumor versus normal tissue (log2 FC = +0.589, t-test p < 0.001).
This table shows molecular features associated with SART3 in patient tissues and cancer cell lines. In patient samples, SART3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SART3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
